Spectral Ai, INC

Spectral AI, Inc. announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026, to lead the global launch of its FDA-cleared DeepView System.

Spectral AI announced the voting results of its 2026 Annual Meeting of Stockholders, where all proposals were approved, and provided an update on its DeepView System following FDA De Novo clearance.

Spectral AI announced that the U.S. Food and Drug Administration has granted De Novo Classification for its DeepView System, authorizing commercial distribution in the United States for burn care.

Spectral AI, Inc. has formalized its CEO's employment terms, including a $500,000 base salary and significant equity grants.

Spectral AI, Inc. announced the appointment of David McGuire as its new Chief Financial Officer, effective May 4, 2026, bringing over 20 years of financial experience to the company.

Spectral AI, Inc. announced its fourth quarter and full year 2025 financial results, highlighting increased cash and progress towards commercializing its DeepView System for burn indication.

Spectral AI reported a significant increase in net loss for Q3 2025, driven by reduced research and development activities as it nears FDA submission, while bolstering its liquidity with new debt and equity financing.

Spectral AI, Inc. reported a reduced net loss for the second quarter of 2025, driven by decreased operating expenses, while advancing its DeepView System with an FDA De Novo application and securing new financing.

Spectral AI reports increased revenue and a shift to net income positive in Q1 2025, driven by government contracts and strategic financing activities.

Spectral AI's Q3 2024 report shows a significant increase in research and development revenue, driven by government contracts, while the company continues to develop its DeepView System.

Spectral AI's Q2 2024 results show a significant increase in research and development revenue, primarily driven by government contracts, while the company continues to navigate financial challenges.

Spectral AI's first quarter 2024 results show a significant increase in research and development revenue, driven by government contracts, while the company continues to develop its DeepView System.

Spectral AI, an AI medical diagnostics company, reported a reduced net loss in 2025 but a decline in revenue, while advancing its DeepView System towards commercialization with key regulatory approvals and significant government funding.

Spectral AI's 2024 annual report reveals a focus on DeepView System development, UKCA marking achievement, and reliance on government funding, with a net loss of $15.3 million.

Spectral AI, Inc. released its 2023 annual report, detailing advancements in its DeepView System and financial performance, including significant government funding and regulatory milestones.

John Michael DiMaio, a Director at Spectral AI, Inc., reported the acquisition of common stock across multiple transactions in late June 2026.

John Michael DiMaio, a Director at Spectral AI, Inc., reported the acquisition of common stock on May 28th and 29th, 2026.

Director John Michael DiMaio acquired 32,233 shares of Spectral AI, Inc. common stock at a weighted average price of $2.61.

Spectral AI, Inc. Director Deepak Sadagopan reports acquisition of 25,000 common stock units and details holdings of restricted stock units and stock options.

Spectral AI, Inc. Director Richard John Cotton reported transactions involving the purchase of company common stock and the vesting of stock options.

Spectral AI, Inc. Director John Michael DiMaio reported the acquisition of common stock and the exercise of stock options on May 15, 2026.

Spectral AI schedules its 2026 Annual Meeting to elect directors and seek shareholder approval for a previously executed share issuance to Hudson Bay.

Spectral AI, Inc. will hold its annual stockholders meeting on May 28, 2025, to elect directors and ratify the appointment of KPMG LLP as the company's independent auditor.

Spectral AI, Inc. will hold its 2025 Annual Meeting of Stockholders on May 28, 2025, to elect directors and ratify the appointment of KPMG LLP as its independent accounting firm.

Spectral AI, Inc. will hold its annual stockholders meeting on May 14, 2024, to vote on the election of directors, ratification of the 2023 Long Term Incentive Plan, appointment of KPMG LLP as the independent auditor, and authorization for the issuance of shares under the Standby Equity Purchase Agreement with YA II PN, Ltd.

Spectral AI announces its 2024 Annual Meeting of Stockholders to be held on May 14, 2024, to vote on director elections, ratification of the 2023 Long Term Incentive Plan, appointment of KPMG LLP as the independent auditor, and authorization for share issuance to YA II PN, Ltd.

Spectral AI has filed a registration statement for the resale of up to 6,369,937 shares of its common stock by YA II PN, LTD (Yorkville).

Spectral AI, Inc. files an amendment to its S-1 registration statement for the offer and sale of up to 4,050,000 shares of common stock by selling stockholder B. Riley Principal Capital II, potentially raising up to $10 million.

Erich Spangenberg has resigned from Spectral AI's board and, along with ELS 1960 Family, L.P., has reduced beneficial ownership below 5%, dissolving a prior investor group.

Hudson Bay Capital Management LP and Sander Gerber have filed a Schedule 13G reporting a 4.99% beneficial ownership stake in Spectral AI, Inc. through warrant holdings.

Hudson Bay Capital Management LP and Sander Gerber have reported a 7.8% beneficial ownership stake in Spectral AI, Inc., including shares issuable from warrants.

Laurence E. Hirsch and Highlander Partners entities report a 3.50% beneficial ownership stake in Spectral AI, Inc. through an amended Schedule 13G filing.